Letter to the Editor
Split Viewer
Blood Res 2015; 50(3):
Published online September 22, 2015
https://doi.org/10.5045/br.2015.50.3.181
© The Korean Society of Hematology
Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia
Hematology Unit, S. Eugenio Hospital Rome, Clinical Pathology, Regina Elena National Cancer Institute, Rome, Italy.
Correspondence to : Pasquale Niscola. Division of Hematology, Piazzale dell'Umanesimo 10, 00144, Rome, Italy. pniscola@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
- Niscola, P, Tendas, A, Scaramucci, L, Giovannini, M, Fratoni, S, de Fabritiis, P. Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome. Blood Res, 2013;48;152-153.
- Tendas, A, Cupelli, L, Siniscalchi, A, et al. Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach. Mediterr J Hematol Infect Dis, 2014;6;e2014020.
- Tobiasson, M, Dybedahl, I, Holm, MS, et al. Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial. Blood Cancer J, 2014;4;e189.
- Efficace, F, Gaidano, G, Breccia, M, et al. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol, 2015;168;361-370.
- Spiriti, MA, Latagliata, R, Niscola, P, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol, 2005;84;167-176.
- Niscola, P, Tendas, A, Giovannini, M, et al. Transfusions at home in patients with myelodysplastic syndromes. Leuk Res, 2012;36;684-688.
- Santini, V, Alessandrino, PE, Angelucci, E, et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res, 2010;34;1576-1588.
- Breccia, M, Voso, MT, Maurillo, L, et al. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. Am J Hematol, 2014;89;565.
- Itzykson, R, Thépot, S, Beyne-Rauzy, O, et al. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?. Leuk Res, 2012;36;397-400.
- Breccia, M, Loglisci, G, Salaroli, A, et al. Combination of azacitidine and ESA in myelodysplastic patients: the need for prospective studies. Leuk Res, 2012;36;682-683.
PDF
Standard view
Export citation
Share Article
Letter to the Editor
Blood Res 2015; 50(3): 181-182
Published online September 22, 2015 https://doi.org/10.5045/br.2015.50.3.181
Copyright © The Korean Society of Hematology.
Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia
Pasquale Niscola*, Andrea Tendas, Roberta Merola, Giulia Orlandi, Laura Scaramucci, and Paolo de Fabritiis
Hematology Unit, S. Eugenio Hospital Rome, Clinical Pathology, Regina Elena National Cancer Institute, Rome, Italy.
Correspondence to: Pasquale Niscola. Division of Hematology, Piazzale dell'Umanesimo 10, 00144, Rome, Italy. pniscola@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- Niscola, P, Tendas, A, Scaramucci, L, Giovannini, M, Fratoni, S, de Fabritiis, P. Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome. Blood Res, 2013;48;152-153.
- Tendas, A, Cupelli, L, Siniscalchi, A, et al. Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach. Mediterr J Hematol Infect Dis, 2014;6;e2014020.
- Tobiasson, M, Dybedahl, I, Holm, MS, et al. Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial. Blood Cancer J, 2014;4;e189.
- Efficace, F, Gaidano, G, Breccia, M, et al. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol, 2015;168;361-370.
- Spiriti, MA, Latagliata, R, Niscola, P, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol, 2005;84;167-176.
- Niscola, P, Tendas, A, Giovannini, M, et al. Transfusions at home in patients with myelodysplastic syndromes. Leuk Res, 2012;36;684-688.
- Santini, V, Alessandrino, PE, Angelucci, E, et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res, 2010;34;1576-1588.
- Breccia, M, Voso, MT, Maurillo, L, et al. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. Am J Hematol, 2014;89;565.
- Itzykson, R, Thépot, S, Beyne-Rauzy, O, et al. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?. Leuk Res, 2012;36;397-400.
- Breccia, M, Loglisci, G, Salaroli, A, et al. Combination of azacitidine and ESA in myelodysplastic patients: the need for prospective studies. Leuk Res, 2012;36;682-683.
Previous Article
